Freenome closed at $11.30 on Nov 4, down 1.48%, within 0.0% of its lowest close since Sep 11. Volume of 757.3K shares was 1.11× its 20-day average (close to normal).
Split-adjusted performance: -30.9% over one month.
Short interest was 4.5M shares at the Oct 15 settlement, up 31.9% from the prior report (9.0% of float, 5.6 days to cover).
No reported quarters with price history yet.
Percentile among 24 companies (100 = best)
Industry medians: 6-month return +36.9%, revenue growth +25.0%, net margin −4.0%, P/E 32.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| FRNMFreenome | $11.30 | −1.48% | — | — | — | — | $1.21B | |
| LMRILumexa Imaging Holdings | $13.10 | +16.76% | +27.4% | — | 1.0% | — | $1.26B | Compare |
| CSTLCastle Biosciences | $35.75 | +1.74% | +44.4% | +20.1% | −2.0% | — | $1.09B | Compare |
| PSNLPersonalis | $15.79 | +0.25% | +160.1% | +30.0% | −141.7% | — | $1.69B | Compare |
| FTREFortrea Holdings | $20.83 | −0.57% | +33.2% | −1.4% | 0.1% | — | $2.01B | Compare |
| FLGTFulgent Genetics | $19.68 | +1.60% | +31.9% | +4.4% | −34.6% | — | $541.5M | Compare |
| CELCCelcuity | $69.24 | −0.69% | −50.3% | — | — | — | $3.39B | Compare |
| VCYTVeracyte | $52.52 | +4.43% | +27.5% | +15.5% | 17.0% | 36.9 | $4.22B | Compare |
| CDNACareDx | $85.86 | −2.95% | +309.8% | +39.3% | 13.8% | 35.1 | $4.51B | Compare |
Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
